Beautiful Virgin Islands

Thursday, Oct 03, 2024

From COVID to Cancer: Pfizer's Shopping Spree Continues with $43 Billion Seagen Acquisition

Pfizer is looking beyond the COVID-19 pandemic and making some major moves in the world of cancer treatments. The pharmaceutical giant has just announced a $43 billion deal to acquire Seagen, a leading innovator in targeted cancer therapies.
This latest acquisition by Pfizer will add four approved cancer therapies to their portfolio, which together generated nearly $2 billion in sales in 2022. Seagen is a pioneer in antibody-drug conjugates, which essentially work like "guided missiles" designed to target and destroy cancer cells while leaving healthy cells unharmed.

CEO Albert Bourla says that this deal will help Pfizer move into an area that is more protected from regulatory and patent issues. It's also a smart move for Seagen, as the Biden administration's Inflation Reduction Act is set to benefit the company's expensive treatments, which will be more accessible to patients with out-of-pocket healthcare spending caps.

Pfizer will pay $229 in cash per Seagen share, a 32.7% premium to Friday's closing price, which sent Seagen's shares soaring to $200 in early trading.

This acquisition comes as Pfizer is preparing for a significant decline in COVID-19 product sales and stiff competition for some of its top-selling drugs. The company expects to generate more than $10 billion in sales from Seagen products alone by 2030, in addition to the $15 billion from its other recent acquisitions.

Pfizer's recent deals include the purchase of Global Blood Therapeutics for $5.4 billion, migraine drug maker Biohaven Pharmaceutical Holding for $11.6 billion, and drug developer Arena Pharmaceuticals for $6.7 billion.

Pfizer's current portfolio of oncology therapies includes 24 approved drugs, while Seagen's includes Adcetris for lymphoma, Padcev for bladder cancers, Tivdak for cervical cancer, and breast cancer treatment Tukysa.

The deal is expected to be completed in late 2023 or early 2024, and while antitrust regulators may closely review it due to its size, Pfizer believes it will eventually be approved.

This is definitely one to watch as Pfizer makes bold moves in the world of cancer treatments and continues to diversify its portfolio beyond COVID-19 products.
Comments

Oh ya 2 year ago
Maybe they are doing this because of the spike in cancer in people who have taken the clot shot. Making money at both ends.

Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
EU Urges UK PM Keir Starmer to Consider Youth Mobility Scheme
British Forces Help Thwart Iranian Missile Attack on Israel
Simon Case Rejoins Garrick Club Amid Mixed Reactions
Investigation into Labour Donor Waheed Alli's Register of Interests
Iceman Drug Boss Jailed: Major Crackdown on £76M Trafficking Operation
UK Evacuates Citizens from Lebanon Amid Growing Tensions
Rise in Vaping Among Non-Smokers in England
Earth Faces Severe Geomagnetic Storm from Solar Flare
Keir Starmer’s Corruption Exposed: Bribes (Yet Again), Broken Promises, and a Rigged System Shielding the Powerful
Bank of America Outage Leaves Customers Unable to Access Accounts, Sparks Concern
Iranian Mullah Claims Israel Used Genies to Hunt Hezbollah Leader
Privacy Concerns Over AI Monitoring of UK Bank Accounts
Robert Jenrick Reveals Daughter's Middle Name as Thatcher
Badenoch Criticizes Civil Servants, Jokes They Are 'Prison-Worthy'
UK Treasury Plans Major Infrastructure Cuts
Kemi Badenoch Criticizes Civil Servants at Conservative Party Conference
Thames Mudlarking Permits Resumed with New Restrictions
Decline in Education for Youth Offenders in England
Jimmy Carter Celebrates 100th Birthday
Iran's Missile Attack on Israel: Defeated but a Significant Escalation
Iran President Lauds Missile Attack on Israel as Decisive Response
Russia Criticizes Biden's Middle East Policies After Iran Attacks Israel
US Dockworkers Strike Halts Half of Nation’s Ocean Shipping
Boris Johnson claims in memoir Queen Elizabeth II had bone cancer
Missile Attack on Israel: A Turning Point for the Ayatollah’s Regime?
Teachers in England Approve 5.5% Pay Rise
Robert Jenrick Criticized for Statements on UK Special Forces
Robert Jenrick Faces Transparency Issues Over Campaign Donations
Phillip Schofield Addresses Firing from ITV
UK Charters Evacuation Flight for Britons in Lebanon
UK Shop Prices Fall at Fastest Rate Since 2021
Keir Starmer Urged to Address Rising Energy Bills
Tom Tugendhat Warns Against Tories Turning into Reform UK
UK to Close Last Coal Power Station After 142 Years
End of Traditional Steelmaking as Tata Closes Port Talbot Blast Furnace
Gaza Hostage Families Urge UK Government to Act
UK Braces for Continued Flooding Amidst New Rain Warnings
Post Office Scandal: Capture IT System Likely Caused Shortfalls
Prince Harry Honors Young Heroes at WellChild Awards in London
BBC Apologises to Amanda Abbington Over Strictly Bullying
UK Government Charters Flight for British Evacuation from Lebanon
Chinese Woman With Two Uteruses Successfully Delivers Twins
Putin Vows to Achieve Goals in Ukraine Amid Ongoing Conflict
Impact and Future Actions Following the Assassination of Hezbollah's Leader
Austrian Election: Far-Right Freedom Party's Historic Victory
Microsoft to Relaunch AI Screenshot Tool Amid Privacy Concerns
India Faces High Concert Ticket Prices: Coldplay and Diljit Dosanjh in Focus
Robert Bourgi Unveils Secrets of French-African Financial Ties
Hollywood Faces Crisis After Strikes and Streaming Wars
Missed Red Flags: Qatar's Controversial Acquisition of Harrods
×